ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
2
views
0
references
Top references
cited by
7
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
3,226
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.
Author(s):
Pankaj Gaur
1
,
Vivek Verma
1
,
Seema Gupta
1
,
Ella Sorani
2
,
Abi Vainstein Haras
3
,
Galia Oberkovitz
3
,
Amnon Peled
4
,
Samir Khleif
1
Publication date
Created:
February 10 2018
Publication date
(Print):
February 10 2018
Journal:
Journal of Clinical Oncology
Publisher:
American Society of Clinical Oncology (ASCO)
Read this article at
ScienceOpen
Publisher
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Gamma Delta T cells
Author and article information
Journal
Title:
Journal of Clinical Oncology
Abbreviated Title:
JCO
Publisher:
American Society of Clinical Oncology (ASCO)
ISSN (Print):
0732-183X
ISSN (Electronic):
1527-7755
Publication date Created:
February 10 2018
Publication date (Print):
February 10 2018
Volume
: 36
Issue
: 5_suppl
Page
: 73
Affiliations
[
1
]
Georgia Cancer Center, Augusta, GA;
[
2
]
BioLineRx Ltd., Modi'in, Israel;
[
3
]
BioLineRx Ltd., Modi’in, Israel;
[
4
]
BioLineRx, Modi’in, Israel;
Article
DOI:
10.1200/JCO.2018.36.5_suppl.73
SO-VID:
149158ba-e841-43ef-a3d8-9e59b7b62b4c
Copyright ©
© 2018
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
3,226
The CXCR4 Antagonist BL-8040 induces a robust mobilization of CD34+CD38–CD45RA–CD90+ CD49f+ HSCs with long-term and secondary myeloid and lymphoid repopulating activity
Authors:
M. ABRAHAM
,
G. Oberkovitz
,
B Bulvik
…
Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57 BL /6 mice.
Authors:
Diego Quiroga
,
Marina C. Muñoz
,
Carolina M. Gil
…
Highly Polarized Optically-Selected BL Lacertae Objects
Authors:
Gary D. Schmidt
,
Dennis L. Means
,
Aleksandar Diamond-Stanic
…
See all similar
Cited by
7
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Authors:
Bruno Bockorny
,
Valerya Semenisty
,
Teresa Macarulla
…
Key chemokines direct migration of immune cells in solid tumors
Authors:
Karan Kohli
,
Venu G Pillarisetty
,
Teresa S Kim
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
Authors:
Franziska Eckert
,
Karin Schilbach
,
Lukas Klumpp
…
See all cited by